Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Multilaboratory evaluation of a viability assay for measurement of opsonophagocytic antibodies specific to the capsular polysaccharides of Streptococcus pneumoniae.
Romero-Steiner S, Frasch C, Concepcion N, Goldblatt D, Käyhty H, Väkeväinen M, Laferriere C, Wauters D, Nahm MH, Schinsky MF, Plikaytis BD, Carlone GM. Romero-Steiner S, et al. Among authors: wauters d. Clin Diagn Lab Immunol. 2003 Nov;10(6):1019-24. doi: 10.1128/cdli.10.6.1019-1024.2003. Clin Diagn Lab Immunol. 2003. PMID: 14607861 Free PMC article.
Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥50 years of age: A randomized trial.
Maréchal C, Lal H, Poder A, Ferguson M, Enweonye I, Heineman TC, Hervé C, Rheault P, Talli J, Wauters D, Oostvogels L. Maréchal C, et al. Among authors: wauters d. Vaccine. 2018 Jul 5;36(29):4278-4286. doi: 10.1016/j.vaccine.2018.05.110. Epub 2018 Jun 11. Vaccine. 2018. PMID: 29903674 Free article. Clinical Trial.
Corrigendum to 'Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥50 years of age: A randomized trial' [Vaccine 36 (2018) 4278-4286].
Maréchal C, Lal H, Poder A, Ferguson M, Enweonye I, Heineman TC, Hervé C, Rheault P, Talli J, Wauters D, Oostvogels L. Maréchal C, et al. Among authors: wauters d. Vaccine. 2019 Feb 21;37(9):1252-1253. doi: 10.1016/j.vaccine.2019.01.022. Epub 2019 Jan 30. Vaccine. 2019. PMID: 30711316 Free article. No abstract available.
Breadth of immune response, immunogenicity, reactogenicity, and safety for a pentavalent meningococcal ABCWY vaccine in healthy adolescents and young adults: results from a phase 3, randomised, controlled observer-blinded trial.
Nolan T, Bhusal C, Beran J, Bloch M, Cetin BS, Dinleyici EC, Dražan D, Kokko S, Koski S, Laajalahti O, Langley JM, Rämet M, Richmond PC, Silas P, Tapiero B, Tiong F, Tipton M, Ukkonen B, Ulukol B, Lattanzi M, Trapani M, Willemsen A, Toneatto D; QUINTET study group. Nolan T, et al. Lancet Infect Dis. 2024 Dec 5:S1473-3099(24)00667-4. doi: 10.1016/S1473-3099(24)00667-4. Online ahead of print. Lancet Infect Dis. 2024. PMID: 39647494
4CMenB Breadth of Immune Response, Immunogenicity, and Safety: Results From a Phase 3 Randomized, Controlled, Observer Blind Study in Adolescents and Young Adults.
Nolan T, Bhusal C, Beran J, Bloch M, Cetin BS, Dinleyici EC, Dražan D, Kokko S, Koski S, Laajalahti O, Langley JM, Rämet M, Richmond PC, Silas P, Tapiero B, Tiong F, Tipton M, Ukkonen B, Ulukol B, Lattanzi M, Trapani M, Willemsen A, Toneatto D; QUINTET study group. Nolan T, et al. Open Forum Infect Dis. 2024 Oct 30;11(11):ofae638. doi: 10.1093/ofid/ofae638. eCollection 2024 Nov. Open Forum Infect Dis. 2024. PMID: 39582508 Free PMC article. Clinical Trial.